AlloVir to wind down PhI­II tri­als for fu­til­i­ty and will re­view strate­gic al­ter­na­tives

AlloVir is pon­der­ing its cor­po­rate fu­ture af­ter find­ing out that its lead an­tivi­ral cell ther­a­py can­di­date is like­ly in­ef­fec­tive.

The biotech had been test­ing posoleu­cel …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER